<DOC>
	<DOC>NCT03038971</DOC>
	<brief_summary>A safety study conducted on subjects ≥16 years old evaluating the safety of 4 intralymphatic injections of 2 different dose levels of the investigational short and tall ragweed product. Biomarkers will be assessed at baseline and at multiple time points post-treatment.</brief_summary>
	<brief_title>Study Evaluating Safety of Ragweed Mix Given by Intralymphatic Node Injections</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis, Allergic</mesh_term>
	<mesh_term>Phenol</mesh_term>
	<criteria>Between the ages of 16 and 65 years old Seasonal Allergic Conjunctivitis (with or without Allergic Rhinitis) to ragweed pollen Positive skin test reaction at screening visit to short ragweed extract Avoid disallowed medications Females of childbearing potential must have pregnancy test and must agree to use an acceptable method of birth control Have blood and urine analysis within normal limits Manifest a positive reaction to a conjunctival allergen challenge with ragweed pollen Have a specific IgE ≥ 0.70 kU/L to short ragweed Have ocular or nasal conditions that could affect subject safety or trial parameters Have a presence of an active sinus, nasal, or ocular infections Have had allergy immunotherapy to ragweed pollen Have a compromised lung function ≤80% of predicted</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>